Critical to further our ability in predicting thrombotic and cardiovascular risk, particularly in the COVID-19 population, we first need to understand the differences seen in the healthy control population and explore the interplay of ACE2 with the coagulation system. This evidence concerns the gene ACE2 and COVID-19.